Opaque diagnostics: clouds cast shadows over sector
This article was originally published in Clinica
Executive Summary
One would have thought that the announcement of the $2.2bn acquisition of private Danish cancer diagnostics company Dako by scientific instrument maker Agilent (www.clinica.co.uk, 18 May 2012), in the same week that the forthcoming American Society for Clinical Oncology (ASCO) conference abstracts were published, would light the touch paper under the field of cancer diagnostics. However, more than one dark commercial cloud cast long shadows over the diagnostics sector.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.